UNMET NEEDS IN
TRADITIONAL CGM TECHNOLOGY

Patients with diabetes receive clinical benefit from continuous glucose monitoring when their sensor is worn more than 70% of the time.[1]

But for some patients using traditional transcutaneous CGM, technology issues can impact acceptance, and adherence.[2]



MOST DESIRED CGM IMPROVEMENTS

Limitations of CGM technology have led some to discontinue use after just the first year.[3]

Current traditional CGM users seek key improvements in their system.[4]

- Longer sensor wear
- Better accuracy
- Better sensor adhesive

EVERSENSE E3
EXCEPTIONAL ACCURACY[5]
OVER 6 MONTHS

2
Sensors per year with Eversense E3

VS

26-52
Sensor changes with traditional CGMs

8.5%*
OVERALL MARD

LONGEST SENSOR WEAR

* Eversense E3 CGM System includes the Eversense E3 Sensor where sacrificial boronic acid (SBA) design modification was incorporated. In the PROMISE study, MARD of 8.5% was observed in the E3 Sensor, and MARD of 9.1% was observed in primary Sensor (which did not have SBA design modification).

EVERSENSE E3 CGM

THE ONLY LONG-TERM CGM THAT LASTS 6 MONTHS WITH A SINGLE SENSOR.

Help your patients break free from the burden of frequent, inconvenient and sometimes painful self-insertions. Freedom from:

- Weekly or bi-weekly hassles of sensor changes and site maintenance.
- Accidental sensor dislodging
- Wasted sensor when transmitter is removed and replaced
- Ongoing CGM supplies to carry and order
- No concerns about an adhesive having to last up to 14 days

Eversense can help simplify the use of CGM, and increase your patients' satisfaction and utilization

REAL WORLD PERFORMANCE OF EVERSENSE[12]

2020 analysis of Eversense users in Europe.



MEDIAN WEAR TIME

Adherence well over the 70% wear time associated with clinical benefit.

AVERAGE TIME IN RANGE (TIR)

Real-world TIR is comparable to -or better than traditional CGM used in open loop systems (CSII and MDI).

WANT A DEMO?
CALL TODAY TO LEARN MORE

844-SENSE4U (736-7348)
ascensiadiabetes.com/eversense

1. Battelino T, et al. (2019). Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From The International Consensus on Time in Range. Diabetes Care 2019(42), 1595-1597. doi: 10.2337/dci19-0028.

2. Engler R, et al. (2017). Adoption barriers for continuous glucose monitoring and their potential reduction with a fully implanted system: Results from patient preference surveys. Clinical Diabetes, 36(1), 50-58. doi: 10.2337/cd17-0053.

3. Yu, S., & Varughese B, et al. (2018). Healthcare resource waste associated with Patient Nonadherence and Early discontinuation of Traditional continuous glucose monitoring in Real-world Settings: A MULTICOUNTRY ANALYSIS. Diabetes Technology & Therapeutics, 20(6), 420-427. doi: 10.1089/dia.2017.0435.

4. Data on File. dQ&A Q1 2021 Panel survey.

5. Garg, S. K. et al. (2021). Evaluation of Accuracy and Safety of the Next-Generation Up to 180-Day Long-Term Implantable Eversense Continuous Glucose Monitoring System: The PROMISE Study. Diabetes Technology & Therapeutics, 24(2), 1-9. DOI: 10.1089/dia.2021.0182.

6. Eversense E3 User Guide December 2020.

7. Dexcom® G6 User Guide Rev Date 12/2020.

8. Freestyle Libre 2 User Guide Rev Date 06/2020.

9. Medtronic Guardian™ Connect User Guide Rev Date 2020.

10. Christiansen, M. P, et al. (2018). A prospective Multicenter Evaluation of the Accuracy of a Novel Implanted Continuous Glucose Sensor: PRECISE II. Diabetes Technology & Therapeutics, 20(3), 197-206. https://doi.org/10.1089/dia.2017.0142.

11. Data on File

12. Tweden, K. S. et al. Longitudinal Analysis of Real-World Performance of an Implantable Continuous Glucose Sensor Insertion and Remobal Cycles. Diabetes Technology & Therapeutics, 22(5), 422-427. https://doi.org/10.1089/dia.2019.0342.

ASCENSIA Diabetes Care

Distributed by Ascensia Diabetes Care
5 Wood Hollow Road, Parsippany, NJ 07054
844-SENSE4U (736-7348)
ascensiadiabetes.com/eversense
Manufactured by Senseonics, Inc. 20451 Seneca Meadows Parkway, Germantown, MD 20876-7005 USA

PP-SENS-GBL-0065

eversense E3
Continuous Glucose Monitoring System

BREAK FREE
FROM TRADITIONAL CGM WITH THE ONLY LONG-TERM 6-MONTH* SENSOR

INTRODUCING THE NEW EVERSENSE E3 CONTINUOUS GLUCOSE MONITORING SYSTEM

ascensiadiabetes.com/eversense

*Up to 6 months

THE ONLY IMPLANTABLE SENSOR FOR LONG-TERM WEAR



ACTUAL SIZE:
3.5 MM X 18.3 MM



SENSOR

The sensor is inserted by a trained health care provider in the upper arm and continuously measures glucose for up to 6 months.

SMART TRANSMITTER

Worn over the sensor, the transmitter wirelessly sends data to user's mobile device; removable[+] and rechargeable with unique on-body vibration alerts.

MOBILE APPLICATION

Displays and updates real-time glucose readings every 5 minutes with intuitive graphical design to show patients if they are in or out of range. Remote real-time monitoring capability – up to 5 people.[†]

THE NEW EVERSENSE E3 CGM

BREAK FREE FROM TRADITIONAL CGM

LONG-TERM CONVENIENCE
One sensor continuously for 6 months

PEACE OF MIND ACCURACY
Exceptional accuracy, including with hypoglycemia

FLEXIBILITY OF WEAR
Easy-on, easy-off transmitter to fit patient's lifestyle[**]

DISCREET ALERTS
Distinct on-body vibration alerts when high or low

GENTLE ON SKIN
Silicone-based fresh daily adhesive for comfort (no residue)

READINGS YOU CAN COUNT ON
Consistent accuracy over 6 months

[**] there is no glucose data generated when the transmitter is removed
[†] on a compatible android or iOS device. For a full list of compatible devices, please visit https://www.ascensiadiabetes.com/eversense/compatibility/

CLINICALLY PROVEN ACCURATE THROUGH 6 MONTHS[5]

Multi-site prospective pivotal clinical trial of 181 type 1 and type 2 diabetes participants.

EXCEPTIONAL ACCURACY - MARD OF 8.5%

Mean absolute relative difference (MARD) across glucose range of 40-400 mg/dL for 180 days with daily calibrations*

**maximum 2 calibrations a day*

ACCURATE, STABLE PERFORMANCE UP TO 6 MONTHS[5]
Percent of readings within 15 mg/dL or 15% of reference value



SENSOR DAYS

HIGHLY ACCURATE — PARTICULARLY IN LOW RANGE[5]
Percent of readings within 15 mg/dL or 15% of reference value



YSI GLUCOSE RANGE

EVERSENSE E3 AND TRADITIONAL CGMS MARD AND SENSOR DURATION*

Eversense E3	8.5%	up to 180 days
Freestyle Libre 2	9.2%	14 days
Dexcom G6	9.9%	10 days
Medtronic	9.1% - 10.6%	7 days

Based on manufacturer user guides[7 & 9]
**adult population 2 calibrations per day or less*

LOW AND HIGH ALERT PERFORMANCE

- Detects **low glucose events** (70 mg/dL) correctly 94% of time
- Detects **high glucose events** (180 mg/dL) correctly 99% of time

SIMPLE IN-OFFICE PROCEDURE

Two brief office visits per year to **insert and remove the sensor in just several minutes.**

SENSOR INSERTION



Sensor inserted with custom inserter

Steri-strips to close

SENSOR REMOVAL



~5-6 mm incision in upper arm under local anesthesia

Sensor removed with clamp

Steri-strips to close

Providers with limited to no surgical experience were able to insert and remove the sensor without difficulty after appropriate training.[10]

EVERSENSE CERTIFICATION FOR PROVIDERS
Training provided to all physicians, nurse practitioners and physician assistants on the sensor insertion and removal. Join over 400 providers and become a certified Eversense provider.[11] Please contact Eversense at 1-844-736-7348.

REIMBURSEMENT
Eversense is covered by many commercial and government (Medicare, VA, Tricare) health plans.

Eversense insertion and removal procedure CPT codes for used in billing.

- **0446T** – Sensor insertion
- **0447T** – Sensor removal
- **0448T** – Sensor removal and reinsertion



Eversense *in vivo* illustration.

INNOVATIVE, SAFE TECHNOLOGY
Non-enzymatic, fluorescent based sensor inserted into the subcutaneous space using aseptic technique. No serious adverse events were reported. Only 59 procedure-related adverse events were reported in 37 out of 181 study participants. Bruising and skin irritation accounted for majority of reported device-related adverse events.[5]